Allergan Aesthetics, an AbbVie company (NYSE: ABBV), has announced a partnership with Sinopharm Group Co., Ltd’s global procurement and supply chain service center at the 5th China International Import Expo (CIIE). The collaboration aims to deepen their partnership in several key areas, including product supply security, new product launches, and the standardization of aesthetic medicine. No financial details were disclosed.
Partnership Objectives
Specifically, the partnership will focus on the following initiatives:
- Continued In-Depth Cooperation: The two companies will continue their collaboration on botulinum toxin type A for injection and Juvéderm, ensuring a stable supply of these key products.
- Market Launch of New Products: They will maintain open communication regarding the market launch in China of Allergan Aesthetics’ new products, ensuring timely and effective market entry.
- Standardization and Industry Policies: The partnership will also address the standardization of practices, industry policies, and other areas within the medical aesthetics industry, aiming to enhance overall industry standards.
Future Prospects
This strategic collaboration underscores Allergan Aesthetics’ commitment to expanding its presence in the Chinese market and enhancing the availability and quality of aesthetic treatments. By working with Sinopharm, Allergan aims to leverage the strengths of both companies to drive innovation and improve patient outcomes in the field of aesthetic medicine.-Fineline Info & Tech
